INSMInsmed Incorporated
Is the business good?
The checks split: nothing decisive, though margins widening.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is INSM?
Insmed Incorporated keeps −74% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- +15%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 76%
R&D as % of revenue
- Gross margin
- 83%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −161% |
| FY2021 | −199% |
| FY2022 | −186% |
| FY2023 | −233% |
| FY2024 | −241% |
| FY2025 | −206% |
Details›
- Gross margin12 months to Q2 2026
- 83%
- Operating margin12 months to Q2 2026
- −74%
- Net margin12 months to Q2 2026
- −77%
- Free cash flow margin
- −71%
- R&D as % of revenue
- 76%
- Revenue, trailing twelve months
- $1.14B
- Free cash flow, trailing twelve months
- −$808M
- Net income, trailing twelve months
- −$875M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
Ranks #38 of 196 by RyuScore